Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia (NCT06710080) | Clinical Trial Compass
RecruitingPhase 3
Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia
Canada168 participantsStarted 2026-04-08
Plain-language summary
The goal of this clinical trial is to learn if icosapent ethyl (Vascepa) works to lessen the amount of inflammation in adults diagnosed with Community-Acquired Pneumonia (CAP). The main question it aims to answer is:
What is the effect of taking Vascepa on inflammation in the arteries in patients with CAP? Researchers will compare the drug Vascepa to a placebo (a look-alike submstance that contains no drug) to see if Vascepa works to reduce inflammation in patients with CAP.
Participants wil:
* take Vacscepa or a placebo twice a day for 6 months
* Visit the clinic 3 times (baseline, 30 days, and 6 months) for checkups and tests
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Hospitalization with CAP (defined as pulmonary infiltration using chest imaging, in addition to other clinical symptoms including fever, cough, and sputum)
✓. age \> 18 years;
✓. given informed consent.
Exclusion criteria
✕. history of cancer within the last 3 years (other than a successfully treated cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix).
✕. pregnancy (all women of child bearing potential will have a negative BHCG test;
✕. breastfeeding;
✕. Women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception.
What they're measuring
1
The change over 6 months in the FDG uptake TBR as a marker of arterial plaque inflammation between the icosapent ethyl and placebo groups
Timeframe: 6 months
Trial details
NCT IDNCT06710080
SponsorOttawa Heart Institute Research Corporation